A Centers for Disease Control and Prevention (CDC) advisory committee is set to meet Thursday to go over data regarding cases of a rare syndrome in people who have received a COVID-19 vaccine.
The Advisory Committee on Immunization Practices, a panel made up of medical and public health experts who make recommendations on vaccinations, will hear from officials on the occurrence of Guillain-Barré syndrome in Americans who have received Johnson & Johnson’s COVID-19 jab, according to a draft agenda.
Presenters include Dr. Narayan Nair, an official with the Food and Drug Administration, Dr. Nicola Klein with Kaiser Permanente Northern California, and panel member Dr. Grace Lee, who chairs the panel’s Vaccine Safety Technical Subgroup.
Nair will go over data from the Vaccine Adverse Event Reporting System, which anyone can submit reports of adverse events to and which is used by federal officials to detect such post-vaccination events. Klein will discuss data from the Vaccine Safety Datalink, which utilizes information from nine healthcare groups, including Kaiser Permanente. Lee will present data from the subgroup she chairs.
After a public comment discussion, Dr. Hannah Rosenblum, a CDC official, will discuss the benefit versus risk of getting the Johnson & Johnson jab.
Guillain-Barré syndrome (CBS) is a rare neurological disorder. Afflicted persons have their immune systems mistakenly attack part of their nervous system. The results can include muscle weakness and, in some cases, paralysis. Most people who contract the syndrome can fully recover.